Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence

DNA and Cell Biology

Volumn 29, Issue 11, 2010, Pages 649-655

  Lacchini, Riccardo ^a   Metzger, Ingrid F ^a   Luizon, Marcelo ^a   Ishizawa, Marília ^a   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B;

ARTICLE; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MICROSATELLITE MARKER; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; DATABASES, GENETIC; DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; LIKELIHOOD FUNCTIONS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 77958611875     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2010.1056     Document Type: Article

References (43)

1. Ahmed, S.H., Clark, L.L., Pennington, W.R., Webb, C.S., Bon-nema, D.D., Leonardi, A.H., McClure, C.D., Spinale, F.G., and Zile, M.R. (2006). Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in pro-teolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113, 2089-2096.
2. Allan, J.A., Docherty, A.J., Barker, P.J., Huskisson, N.S., Reynolds, J.J., and Murphy, G. (1995). Binding of gelatinases A and B to type-I collagen and other matrix components. Bio-chem J 309 (Pt 1), 299-306.
3. Baraban, E., McCoy, L., and Simon, P. (2008). Increasing prevalence of gestational diabetes and pregnancy-related hypertension in Los Angeles County, California, 1991-2003. Prev Chronic Dis 5, A77.
4. Belo, V.A., Souza-Costa, D.C., Lana, C.M., Caputo, F.L., Mar-caccini, A.M., Gerlach, R.F., Bastos, M.G., and Tanus-Santos, J.E. (2009). Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 42, 984-990.
5. Bryc, K., Auton, A., Nelson, M.R., Oksenberg, J.R., Hauser, S.L., Williams, S., Froment, A., Bodo, J.M., Wambebe, C., Tishkoff, S.A., and Bustamante, C.D. (2010). Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci USA 107, 786-791.
6. Castro, M.M., Rizzi, E., Figueiredo-Lopes, L., Fernandes, K., Bendhack, L.M., Pitol, D.L., Gerlach, R.F., and Tanus-Santos, J.E. (2008). Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198, 320-331.
7. Castro, M.M., Rizzi, E., Prado, C.M., Rossi, M.A., Tanus-Santos, J.E., and Gerlach, R.F. (2010). Imbalance between matrix me-talloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 29, 194-201.
8. Castro, M.M., Rizzi, E., Rodrigues, G.J., Ceron, C.S., Bendhack, L.M., Gerlach, R.F., and Tanus-Santos, J.E. (2009). Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 46, 1298-1307.
9. Coussens, L.M., and Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chem Biol 3, 895-904.
10. Demacq, C., de Souza, A.P., Machado, A.A., Gerlach, R.F., and Tanus-Santos, J.E. (2006). Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365, 183-187.
11. Demacq, C., Vasconcellos, V.B., Marcaccini, A.M., Gerlach, R.F., Machado, A.A., and Tanus-Santos, J.E. (2009). A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacoge-nomics J 9, 265-273.
12. Demacq, C., Vasconcellos, V.B., Marcaccini, A.M., Gerlach, R.F., Silva, W.A., Jr., and Tanus-Santos, J.E. (2008). Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 46, 57-63.
13. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2, 161-174.
14. Fernandes, K.S., Brum, D.G., Sandrim, V.C., Guerreiro, C.T., Barreira, A.A., and Tanus-Santos, J.E. (2009). Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol 214, 128-131.
15. Forouhi, N.G., and Sattar, N. (2006). CVD risk factors and ethnicity-a homogeneous relationship? Atheroscler Suppl 7, 11-19.
16. Fortuna, G.M., Figueiredo-Lopes, L., Dias-Junior, C.A., Gerlach, R.F., and Tanus-Santos, J.E. (2007). A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int J Cardiol 114, 22-27.
17. Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S.N., Rotimi, C., Adeyemo, A., Cooper, R., Ward, R., Lander, E.S., Daly, M.J., and Altshuler, D. (2002). The structure of haplotype blocks in the human genome. Science 296, 2225-2229.
18. Ghafoor, A., Jemal, A., Ward, E., Cokkinides, V., Smith, R., and Thun, M. (2003). Trends in breast cancer by race and ethnicity. CA Cancer J Clin 53, 342-355.
19. Goncalves, F.M., Jacob-Ferreira, A.L., Gomes, V.A., Casella-Filho, A., Chagas, A.C., Marcaccini, A.M., Gerlach, R.F., and Tanus-Santos, J.E. (2009). Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 403, 173-177.
20. Kubo, A., and Corley, D.A. (2004). Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 99, 582-588.
21. Marcaccini, A.M., Meschiari, C.A., Zuardi, L.R., de Sousa, T.S., Taba, M., Jr., Teofilo, J.M., Jacob-Ferreira, A.L., Tanus-Santos, J.E., Novaes, A.B., Jr., and Gerlach, R.F. (2009a). Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. J Clin Periodontol Dec 7 [Epub ahead of print].
22. Marcaccini, A.M., Novaes, A.B., Jr., Meschiari, C.A., Souza, S.L., Palioto, D.B., Sorgi, C.A., Faccioli, L.H., Tanus-Santos, J.E., and Gerlach, R.F. (2009b). Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. Clin Chim Acta 409, 117-122.
23. Marroni, A.S., Metzger, I.F., Souza-Costa, D.C., Nagassaki, S., Sandrim, V.C., Correa, R.X., Rios-Santos, F., and Tanus-Santos, J.E. (2005). Consistent interethnic differences in the distribution of clinically relevant endothelial nitric oxide synthase (eNOS) genetic polymorphisms. Nitric Oxide 12, 177-182.
24. Martinez, M.L., Castro, M.M., Rizzi, E., Fernandes, K., Demacq, C., Bendhack, L.M., Gerlach, R.F., and Tanus-Santos, J.E. (2008a). Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 591, 224-230.
25. Martinez, M.L., Lopes, L.F., Coelho, E.B., Nobre, F., Rocha, J.B., Gerlach, R.F., and Tanus-Santos, J.E. (2006). Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47, 117-122.
26. Martinez, M.L., Rizzi, E., Castro, M.M., Fernandes, K., Bend-hack, L.M., Gerlach, R.F., and Tanus-Santos, J.E. (2008b). Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 599, 110-116.
27. Martins-Oliveira, A., Speciali, J.G., Dach, F., Marcaccini, A.M., Goncalves, F.M., Gerlach, R.F., and Tanus-Santos, J.E. (2009). Different circulating metalloproteinases profilesinwomen with migraine with and without aura. Clin Chim Acta 408, 60-64.
28. Montenegro, M.F., Barbosa, F., Jr., Sandrim, V.C., Gerlach, R.F., and Tanus-Santos, J.E. (2006). Ethnicity affects the distribution of delta-aminolevulinic acid dehydratase (ALAD) genetic variants. Clin Chim Acta 367, 192-195.
29. Muniz, J.J., Izidoro-Toledo, T.C., Metzger, I.F., Sandrim, V.C., and Tanus-Santos, J.E. (2009). Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol 28, 567-572.
30. Nagase, H., and Woessner, J.F., Jr. (1999). Matrix metallopro-teinases. J Biol Chem 274, 21491-21494.
31. Palei, A.C., Sandrim, V.C., Duarte, G., Cavalli, R.C., Gerlach, R.F., and Tanus-Santos, J.E. (2010). Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta 411, 874-877.
32. Price, S.J., Greaves, D.R., and Watkins, H. (2001). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific tran-scriptional regulation. J Biol Chem 276, 7549-7558.
33. Rezende, V.B., Barbosa, F., Jr., Montenegro, M.F., Sandrim, V.C., Gerlach, R.F., and Tanus-Santos, J.E. (2007). An interethnic comparison of the distribution of vitamin D receptor genotypes and haplotypes. Clin Chim Acta 384, 155-159.
34. Shimajiri, S., Arima, N., Tanimoto, A., Murata, Y., Hamada, T., Wang, K.Y., and Sasaguri, Y. (1999). Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett 455, 70-74.
35. Souza-Costa, D.C., Figueiredo-Lopes, L., Alves-Filho, J.C., Semprini, M.C., Gerlach, R.F., Cunha, F.Q., and Tanus-Santos, J.E. (2007). Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit Care Med 35, 239-245.
36. Souza-Costa, D.C., Zerbini, T., Palei, A.C., Gerlach, R.F., and Tanus-Santos, J.E. (2005). L-arginine attenuates acute pulmonary embolism-induced increases in lung matrix metalloproteinase-2 and matrix metalloproteinase-9. Chest 128, 3705-3710.
37. Spinale, F.G. (2007). Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87, 1285-1342.
38. Stephens, M., Smith, N.J., and Donnelly, P. (2001). A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68, 978-989.
39. Tanus-Santos, J.E., Desai, M., and Flockhart, D.A. (2001). Effects of ethnicity on the distribution of clinically relevant endothe-lial nitric oxide variants. Pharmacogenetics 11, 719-725.
40. Uzuelli, J.A., Dias-Junior, C.A., and Tanus-Santos, J.E. (2008). Severity dependent increases in circulating cardiac troponin I and MMP-9 concentrations after experimental acute pulmonary thromboembolism. Clin Chim Acta 388, 184-188.
41. van den Born, B.J., Koopmans, R.P., Groeneveld, J.O., and van Montfrans, G.A. (2006). Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens 24, 2299-2304.
42. Wall, J.D., and Pritchard, J.K. (2003). Haplotype blocks and linkage disequilibrium in the human genome. Nat Rev Genet 4, 587-597.
43. Zhang, B., Ye, S., Herrmann, S.M., Eriksson, P., de Maat, M., Evans, A., Arveiler, D., Luc, G., Cambien, F., Hamsten, A., Watkins, H., and Henney, A.M. (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99, 1788-1794.